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Changes in heparan sulfate correlate with increased glomerular per-
meability. The glomerular capillary wall functions as both a size-
selective and charge-selective barrier. Heparan sulfate is known to be
an important component of the charge-selective barrier to filtration of
polyanions. We studied the alterations in both the charge and size
selectivity barriers in a model of experimental membranous nephrop-
athy in the rabbit. The fractional clearance of both charged and
uncharged dextrans compared to inulin was measured. Sulfate incor-
poration into glycosaminoglycans was measured and the glomerular
heparan sulfate was isolated and biochemically characterized. Membra-
nous nephropathy in the rabbit was induced with daily injections of
cationic bovine serum albumin. After three weeks of injection animals
had 735 196 mg/24 hours of protein excretion. There was no change
in [35SJ incorporation in 24 hours by experimental animals, 440 91
DPM/mg dry weight of glomeruli, N = 9 versus 410 98, N = 11 in
controls. The percentage of [35S] incorporated into heparan sulfate
versus chondroitin sulfate was decreased, 60% 3 versus 79% 2, P
<0.001. Heparan sulfate from membranous nephropathy eluted from
ion exchange chromatography in a lower molarity salt, indicating a
lower effective charge. Fractional clearance of neutral dextrans was
significantly increased in membranous nephropathy for dextrans greater
than 48 A, while fractional clearance of dextran sulfates was signifi-
cantly increased compared to controls for dextrans greater than 32 A.
Thus, in membranous nephropathy there is loss of both charge selec-
tivity and size selectivity. The loss of charge selectivity correlated with
a change in the structure of the glomerular heparan sulfate. The change
in structure of the heparan sulfate could be the initiating event in the
altered glomerular permeability of experimental membranous nephrop-
athy.
The glomerular capillary wall functions as a semipermeable
membrane allowing the passage of water and small solutes, but
excluding macromolecules to form a nearly protein-free ultra-
filtrate [1—3]. The basement membrane of the glomerular capil-
lary consists of a collagen backbone and fixed anionic macro-
molecules [4, 51. These anionic sites consist predominantly of
heparan sulfate proteoglycan [5—71. Recently another glomeru-
lar polyanion, podocalyxin, has been identified as a sialoprotein
on glomerular epithelial cells [81.
The glomerular basement membrane functions as both a
size-selective and charge-selective barrier [1, 2]. Large circu-
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lating macromolecules will be excluded on the basis of size.
Negatively-charged circulating plasma proteins are excluded on
the basis of charge as well. Increased permeability of the
glomerular basement membrane to plasma proteins may be due
to alterations in the size selectivity, the charge selectivity or
both [1, 2].
Membranous nephropathy is the most common form of
glomerular injury leading to idiopathic nephrotic syndrome in
the adult [9]. In this disease immune deposits form in the
subepithelial space between the basement membrane and the
epithelial foot processes [9]. The alterations in glomerular
basement membrane structure and function which lead to the
increased permeability in this disorder remain poorly under-
stood.
This study was performed to identify the structural and
functional alterations of the glomerular capillary wall in an
animal model of membranous nephropathy. In this model,
subepithelial immune deposits are induced in rabbits by daily
injections of a cationic antigen, chemically-modified bovine
serum albumin [10]. The functional characteristics of the base-
ment membrane were determined by measuring the clearance of
variously-sized dextrans both charged and uncharged. The
structural aspects of the basement membrane were studied by
isolating and biochemically characterizing glomerular heparan
sulfate, an important dominant component of the anionic sites
[11, 12].
This is the first study to compare both structure and function
of the glomerular capillary wall in a model of proteinuria. It is
important to correlate both of these since the structural changes
of the glomerular capillary wall probably underlie the functional
changes which are found in states of altered glomerular perme-
ability.
Methods
Induction of rabbit membranous nephropathy
Crystalline fraction V bovine serum albumin (BSA) (Miles
Laboratories, Elkhart, Indiana, USA) was used to prepare
cationic BSA. Cationization was accomplished by carbodiimide
activation of carboxyl groups and substitution of ethylenedi-
amine according to a modification of the method of Hoare and
Koshland as described previously [13]. The isoelectric point of
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the cationic BSA was 9.2 to 9.5 as measured in a thin-layer
polyacrylamide gel.
New Zealand white rabbits (1.5 to 2.0 kg) were used. Each
animal received a primary intravenous immunization with 1 mg
cationic BSA and 1 jsg endotoxin (Difco Laboratories, Detroit,
Michigan, USA) dissolved in phosphate-buffered saline, pH
7.2. One week later, daily (6 days per week) injections of
cationic BSA (25 mg i.v.) were begun. The cationic BSA was
dissolved in phosphate buffered saline and centrifuged before
injection [10]. The animals were housed in individual cages and
fed a standard diet. Twenty-four hour urine collections were
obtained weekly.
Urine protein was measured by the sulfosalicylic acid method
on the 24-hour urine collection using whole serum as a standard
(Lab-Trol, Dade Division, America Hospital Supply Corp.,
Miami, Florida, USA). Protein excretion in normal rabbits is up
to 18 mg/24 hours in our laboratory.
Isolation of glornerular heparan sulfate
The method followed for the isolation of total glomerular
glycosaminoglycans was that used by Linker and Hovingh for
the isolation of glycosaminoglycans from bovine lung [14].
Briefly, after three weeks of daily injections of cationic BSA,
rabbits were injected with 2 mCi of [35S] sulfate, and 24 hours
later they were sacrificed and the kidneys obtained. The gb-
meruli were isolated by differential sieving as described previ-
ously, washed extensively with cold 0.02 M phosphate buffered
saline, pH 7.2 [15].
Glomeruli were acetone dried and weighed. The dried gb-
meruli were taken up in a 1 ml solution containing papain
(Worthington Company, Freehold, New Jersey, USA) and
incubated at 60°C for 24 hours to release glycopeptides. At this
time, 1 mg of carrier chondroitin sulfate (Sigma Chemical
Company, St. Louis, Missouri, USA) was added. The glycos-
aminoglycans were precipitated with cetylpyridinium chloride.
This precipitate was centrifuged, washed with sodium chloride
saturated 95% ethanol and finally with 95% ethanol and dried.
The glycosaminoglycans were further purified by removing
most of the remaining proteins and nucleic acids by precipita-
tion with trichioracetic acid. The supernatant was adjusted to
pH 5 with sodium acetate and glycosaminoglycans precipitated
with three volumes of 95% ethanol. The ethanol precipitated
glycosaminoglycans were dried, taken up in a known volume,
and the radioactivity measured.
In order to identify glycosaminoglycans, the sample was
treated with testicular hyaluronidase (Sigma Chemical Co.) in
0.15 M NaCl and 0.1 M acetate, pH 5.6 at 37°C for 24 hours to
degrade chondroitin sulfate. The solution was then placed on a
Sephadex G 50 column (5 x 550 mm) and eluted in 0.15 M NaCI
in 10% ethanol. Elution patterns were determined by monitor-
ing the radioactivity and the uronic acid of the carrier. The
included volume contained over 95% of the uronic acid (due to
the degraded carrier) and therefore, the associated radioactivity
was also derived from chondroitin sulfate. The radioactivity of
the void volume was due to heparan sulfate, as indicated by the
resistance to testicular hyaluronidase and verified by nitrous
acid degradation [16]. The percent chondroitin sulfate was
determined.
Uronic acid was measured by a colorimetric method using
meta-hydroxydiphenyl [17]. This uronic acid method is insen-
sitive to pentose sugars and hence nucleic acid is unlikely to
interfere with the assay [17].
Quantification and characterization of heparan sulfate
As heparan sulfates can be very heterogeneous, the heparan
sulfate fraction obtained from the Sephadex G-50 column was
further fractionated on a Bio-Rad AGI-X2 (Cl-) (Bio-Rad Lab,
Richmond, California, USA) ion exchange column (4x 1 cm) to
determine the distribution of radioactivity within the heparan
sulfate fractions [14]. The column was eluted in a stepwise
manner with 8 ml each of 1.0 M, 1.25 M, and 2.0 M NaC1. Each
fraction subsequently referred to as 1.0 M, 1.25 M or 2.0 M was
dialyzed, dried and taken up in a known volume. The radioac-
tivity was measured and the uronic acid determined for each
fraction. Since the carrier chondroitin sulfate had been removed
effectively with the testicular hyaluronidase and the Sephadex
G-50 column, the measurement of uronic acid determined the
actual amount of heparan sulfate present. The specific activity
of the [35S] sulfate containing heparan sulfate was calculated.
Molecular weights of the heparan sulfates were determined by
gel filtration on Sephadex G-150 without earners.
The heparan sulfates were further characterized by treatment
with two enzymes which degrade heparan sulfate. Heparinase
and heparitinase were prepared from flavobacteria as previ-
ously described [18]. Purified heparinase, free of heparitinase,
was used in 0.1 M sodium acetate, pH 7.0 at 30°C for 24 hours
with heparin as a carrier. Heparitinase was used by the same
method with heparan sulfate as carrier. The degradation prod-
ucts were placed on Sephadex G-50 column in a solution of 0.2
M sodium chloride and 10% ethanol. Elution profiles were
followed by measurement of radioactivity and by ultraviolet
absorption at 232 nm for following the carriers. Results are
expressed as percentage of total reactivity in the disaccharide
fractions, indicating extent of degradation. This characteriza-
tion was carried out on the two dominant fractions obtained
from the ion exchange column, the 1.0 M and the 1.25 M
fractions, to determine if there were any structural differences
in heparan sulfate between control and experimental glomeruli.
Clearances of inulin and dextrans
Clearances of inulin, polydisperse neutral dextran and poly-
disperse anionic dextran sulfate were determined simulta-
neously using a double-label technique after three weeks of
injection of cationic BSA [19, 20]. Neutral dextran of a broad
range of molecular radii (15 to 70 A) was obtained by mixing
equal parts of dextran T70 (Pharmacia Fine Chemicals,
Piscataway, New Jersey, USA) and T20 (Sigma). The mixture
was radiolabeled with tntium by oxidation with periodate,
followed by reduction with tritiated sodium borohydride, using
previously described techniques [19]. The product was dialyzed
extensively and frozen until used. The same mixture of neutral
dextrans served as substrate for the formation of [35S] radiola-
beled dextran sulfate by the method of Woods and Mora [21].
Briefly, 40 ml anhydrous pyridine was placed in a flask, and six
ml of chlorosulfonic acid, containing trace [35S] sulfate, was
added drop wise with vigorous stirring. The reaction mixture
was brought to 50°C and 5 grams of polydispersed neutral
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[35S04] Incorporation
Control
glomeruli
N = 11
Experimental
glomeruli
N = 9
DPM/mg dry wt of glomeruli
% [35SO] in heparan sulfatec
410 98
79% 2.6
440 91
60% 3.5%"
Total heparan sulfate uronic acid 0.44 0.080 0,45 0.066a
j.g/mg dry wt of glomeruli
dextran mixture added. The reaction mixture was maintained
with stirring for four hours, and was then neutralized with
sodium hydroxide to pH 7. The dextran sulfates were precip-
itated from solution with ethanol and dialyzed against deionized
distilled water. Sodium chloride was added to bring the solution
to normality and the products stored frozen until used. The
isoelectric point of the dextran sulfate was determined and was
found to be 4.5 to 5.4.
In the current studies, rabbits were anesthetized with
ketamine and xylazine and placed on a heated operating table.
Polyethelene catheters were placed in the right femoral artery
and vein and the arterial line connected to pressure tranducer
(Statham Instruments, Cambridge, Massachusetts). The left
ureter was exposed via a paramedian incision and a ureteral
catheter inserted. The rabbit was then placed in a restraining
cage and allowed to awaken. Normal saline was infused intra-
venously at 0.3 mI/mm during the surgery and recovery. When
the rabbit was fully awake a solution of normal saline containing
3% inulin, [3H] dextran and [35S] dextran sulfate was adminis-
tered as a bolus of 3 ml over two minutes, followed by
continuous infusion of 0.3 ml/min. Neutral dextrans and dex-
tran sulfates, with molecular radii of 15 to 70 A, were infused.
After a 30-minute equilibration period, blood collection was
begun by continuous withdrawal of 0.1 ml per minute from the
arterial line. Tubular transit time was measured by observing
the time from intravenous injection of lissamine green dye to its
appearance at the tip of the ureteral catheter. Urine collection
was then begun and each collection period lasted 30 minutes.
Inulin concentrations in plasma and urine were determined
using the anthrone colorimetric assay [22J. Samples of urine and
plasma were mixed with an equal volume of 20% sucrose
solution containing blue dextran (3 mg/mI) and applied to 2.6)<
89 cm column of polyacrylamide-agrose mixture (Utrogel
Aca-34 and Aca-44) equilibrated with 0.05 M sodium phosphate
buffer, pH 7.4, containing 0.1 M sodium chloride and 0.2 g/liter
of sodium azide. Ten ml fractions were collected. These frac-
tions were then counted in a scintillation counter (Beckman
Instruments, Fullerton, California, USA). Absolute activities
were calculated for tritium and [355] in each sample.
Inulin clearance was used as a measure of single kidney
glomerular filtration rate. Fractional clearances of neutral dex-
tran and dextran sulfate were computed using the following
formulae for each fraction from radius 15 to 66 A
Table 2. Distribution of heparan sulfate on ion exchange
chromatography
Fraction
1.0 M NaCl
1.25 M NaCI
2.0 M NaCI
<0.01
<0.01
>0.05
UTritium/PTritium
Feneutra, dex =
U[S35]/P[S35]
Fedextranso4 =
Five control rabbits had polydisperse neutral dextran clear-
ances and dextran sulfate clearances measured. Four experi-
mental rabbits had neutral dextran clearances and dextran
sulfate clearances measured.
Statistical analysis
All values are expressed as mean standard error of the
mean. Results were evaluated by the unpaired Student's f-test
and for non-parametric data by the Mann-Whitney rank sum
method [23]. P values less than 0.05 were regarded as signifi-
cant.
Results
Induction of rabbit membranous nephropathy
After three weeks of injections of cationic BSA, urinary
protein excretion was 735 196 mg/24 hours in experimental
animals and less than 18 mg124 hours in control animals, P <
0.001. Single kidney GFR, measured by inulin clearance, was
1.77 0.33 mllmin in the experimental group and 4.63 0.20
mllmin in the control group.
All glomeruli in the experimental group showed 3 + to 4+
granular staining for rabbit IgG and rabbit C3 by immunofluo-
rescence and trace to 1+ staining for BSA. Frequent large
subepithelial deposits associated with foot process effacement
were seen by electron microscopy in all experimental animals
as previously described [24].
Characterization of heparan sulfate
Table I shows that total [35S] sulfate incorporation was not
different between control and experimental animals, being 410
98 DPM/mg dry weight of glomeruli, N= 11, in controls
versus 440 91, N=9, in experimental rabbits, P> 0.05. The
percentage of [35S] sulfate incorporated into heparan sulfate
was significantly decreased in experimental glomeruli, 79
2.6%, N=ll, in controls versus 60 3.5%, N=9, P <0.001.
Total heparan sulfate as measured by uronic acid was not
Table 1. Quantitation of glycosaminoglycans
a P> 0.05 compared to control glomeruli
b p < 0.001 compared to control glomeruli
' Remainder in chondroitin sulfate
Control
glomeruli
N = 11
27.2% 1.85
45.8% 2.27
26.1% 1.53
P
value
Experimental
glomeruli
N=9
38.9% 3.50
35.1% 2.32
23.9% 1.55
Uinulin X V
Cinulin =
Pinulin
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different between the two groups, 0.44 0.080 xg/mg dry
weight of glomeruli versus 0.45 0.066 jxg, P > 0.05,
Results of the distribution of heparan sulfate on ion exchange
chromatography are shown in Table 2. Experimental glomeruli
had a shift in heparan sulfate from the 1.25 M fraction to the 1.0
M fraction as compared to controls. The ratio of heparan sulfate
in the 1.0 M fraction to the 1.25 M fraction was 0.80 0.182 in
controls and 1.28 0.314 in experimentals, P < 0.01. The
specific activity of the heparan sulfate expressed as DPM/j.tg
uronic acid is shown in Table 3. As would be expected from the
charge distribution, there was an increase in specific activity in
the 1.25 M fraction compared to 1.0 M fraction in controls, while
in experimental glomeruli the specific activity did not increase
significantly.
The molecular weight of the heparan sulfate in the 1.0 M and
1.25 M fractions was similar in both control and experimental
groups, with elution Kay's of 0.3 to 0.5 and corresponding Mr of
11,200 to 15,900.
The yield of disaccharides, from Sephadex G-50 after treat-
ment of the 1.0 M and 1.25 M fractions with two heparan sulfate
degrading enzymes, is shown in Table 4. Heparitinase degrada-
tion of the heparan sulfate was similar in both groups. Hepa-
rinase degradation showed different yields of the 1.0 M NaCI
fraction between control and experimental glomeruli. The ex-
perimental glomeruli 1.0 M fraction was less degraded by
heparinase compared to the control 1.0 M fraction, suggesting a
decreased iduronic acid-sulfate content [25].
Fraction clearance of charged and uncharged dextrans
Fractional clearances were calculated for neutral dextran and
for dextran sulfate as a function of effective dextran molecular
radius over the range of radii 15 to 66 A. In control rabbits,
fractional clearance of neutral dextran approach unity for
molecular radii less than 18 A. Fractional clearances decreased
progressively with increasing radii over the range 20 to 60 A and
appeared to reach a plateau of 0.00 12 for radii greater than 60 A
as shown in Table 5 and Figure 1. Fractional clearance of
dextran sulfate was less than that of neutral dextran for all
molecular radii studied. Over the range of 15 to 45 A the
clearance decreased progressively with increasing molecular
radius as shown in Table 5 and Figure 2. In this range, clearance
of neutral dextrans exceeded that of dextran sulfate by a factor
of at least 6.8. Fractional clearance of dextran sulfate of radius
greater than 51 A reached a plateau of about 0.00036.
The induction of membranous nephropathy in the experimen-
tal group caused significant differences in the clearances of both
neutral and charged dextran molecules. Fractional clearance of
Table 3. Specific activity of the heparan sulfate in the 1.0 M and
1,25 M NaC1 fractions
DPM/zg uronic acid
Control glomeruli Experimental glomeruli
Fraction N= 8 N= 9
1.0 M NaCI 605 75 678 180
1.25 ss NaCI 924 118
Fractional clearances of neutral dextrans
a P < 0.05 compared to the 1.0 M fraction
b P> 0.05 compared to the 1.0 si fraction
Table 5.
Dextran radius
A
15
17
18
19
20
21
23
25
26
28
30
32
34
36
39
42
44
47
51
54
58
62
66
Table 4. Percentage yield of disaccharides after treatment of heparan
sulfate subfractions with heparitinase and heparinase
Heparan sulfate degradative
enzyme
Heparan sulfate subfraction Heparitinase Heparinase
Control 1.0 M NaCl fraction 34% 21%
Experimental 1.0 M NaC1 fraction 36% 9%
Control 1.25 M NaC1 fraction 24% 11%
Experimental 1.25 M NaC1 fraction 22% 13%
Control N = 5
mean SxM
0.952 0.095
0.933 0.090
0.913 0.094
0.854 0.074
0.812 0.069
0.734 0.062
0.625 0,053
0.507 0.037
0.400 0.025
0.301 0.021
0.228 0.021
0.191 0.032
0.156 0.038
0.116 0.021
0.080 0.014
0.052 0.009
0.025 0.005
0.012 0.002
0.006 0.001
0.003 0.0003
0.002 0.0003
0.001 0.0003
0.001 0.0003
Experimental N = 4
mean SEM
0.805 0.049
0.796 0.059
0.760 0.064
0.703 0.058
0.633 0.064
0.547 0.059
0.462 0.048
0.379 0.036
0.290 0.032
0.232 0.020
0.181 0.021
0.128 0.015
0.094 0.015
0.076 0.010
0.052 0.005
0.034 0.006
0.025 0.006
0.018 0.005
0.011 0.003
0.008 0.002
0.005 0.001
0.004 0.001
0.005 0.001
P value
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
<0.05
<0.05
<0.05
<0.05
<0,05
1.0
0.1
C-)
C
° 0.01
0.001
Fig. 1. Fractional clearance of neutral dextrans in the experimental
membranous nephropathy group (dashed line) compared to the control
group (solid line). Fractional clearances are plotted as function of
effective neutral dextran radius. Results are expressed as mean SEM.
* P < 0.05.
35 45
Neutral dextran radius, A
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1.0
0.1
U
0.01'a
C)
0.001'
Dextran sulfate radius, A
Fig. 2. Fractional clearance of dextran sulfates in the experimental
membranous nephropathy group (dashed line) compared to the control
group (solid line). Fractional clearances are plotted as function of
effective dextran sulfate radius. Results are expressed as mean SaM.
* P < 0.05.
neutral dextran decreased as a function of increasing molecular
radius, in a manner similar to control animals, as shown in
Table 5 and Figure 1. However, the fractional clearance of
molecules less than 40 A radius was less in the experimental
group than controls, while clearance of neutral dextrans of
radius greater than 48 A was significantly increased in the
experimental group, as compared to controls.
Fractional clearance of dextran sulfate in the experimental
group was increased compared to controls over the entire range
of molecular radii studied, as shown in Table 6 and Figure 2.
However, the difference was not significant at small molecular
radii (< 30 A) and reached significance only for radii greater
than 32 A. Clearance of dextran sulfate of radius 15 A was 0.144
in the experimental group and decreased with increase in
molecular radius to reach a plateau of 0.001 for radii greater
than 58 A.
Discussion
A variety of hypotheses have been proposed to explain
changes in the clearance of macromolecules associated with
experimental or naturally occurring glomerular injury. As the
passage of large molecules appears to depend on their size as
well as their charge, any hypothesis suggested must take both
parameters into account.
We have here used a model of membranous nephropathy to
address the question of what basic processes are involved in
clearance changes. In the present study the clearance of neutral
dextrans diminished markedly with increasing size. The frac-
tional clearance of the largest radius studied (65 A) was less by
a factor of 790 than the clearance of the smallest dextran. The
charge-selectivity of the glomerular capillary wall is also dem-
onstrated by the marked reduction in fractional clearance of
dextran sulfate compared to clearance of neutral dextran of the
same molecular radius. At all radii studied, the fractional
Table 6. Fractional clearances of dextran sulfates
Dextran radius
A
Control N = 5
mean SEM
Experimental N = 4
mean SEM P value
15 0.139 0.020 0.144 0.010 NS
17 0,125 0.019 0.132 0.015 NS
18 0.111 0.017 0.111 0.008 NS
19 0.097 0.013 0.096 0.006 NS
20 0.076 0.011 0.082 0.007 NS
21 0.061 0.008 0.065 0.005 NS
23 0.049 0.006 0.050 0.005 NS
25 0.037 0.005 0.040 0.004 NS
26 0.027 0.004 0.031 0.002 NS
28 0.018 0.002 0.023 0.001 NS
30 0.012 0.001 0.016 0.0006 NS
32 0.008 0.001 0.012 0.0008 NS
34 0.005 0.0004 0.008 0.0009 <0.05
36 0.003 0.0002 0.005 0.0013 <0.05
39 0.001 0.0001 0.004 0.0017 <0.05
42 0.001 0.0000 0.003 0.0015 <0.05
44 0.0005 0.0000 0.002 0.0010 <0.05
47 0,0005 0.0001 0.002 0.0002 <0.05
51 0.0005 0.0001 0.001 0.0002 <0.05
54 0.0004 0.0001 0.001 0.0001 <0.05
58 0.0003 0.0001 0.001 0,0001 <0.05
62 0.0004 0.0001 0.001 0.0002 <0.05
66 0.0004 0.0001 0.001 0.0002 <0.05
clearance of dextran sulfate was less than that of neutral
dextran by a factor of four or greater.
Leakage of plasma proteins by the glomerular capillary wall
in glomerulonephritis can occur due to loss of the size selectiv-
ity, loss of the charge selectivity or loss of both [1, 2]. In the
model of membranous nephropathy studied here we found
decreased clearance of small sized neutral dextran (3 to 48 A),
but with neutral dextrans of molecular radii 48 A and greater the
fractional clearance was increased compared to controls. Thus
there is an alteration in the size-selectivity of the capillary wall.
We also found increased fractional clearance of dextran sulfate
at all molecular radii studied compared to control rabbits. This
increased clearance of dextran sulfate was statistically signifi-
cant for dextran sulfates of molecular radii 32 A and greater.
Clearly the increased clearance of dextran sulfate from molec-
ular radii 32 to 48 A cannot be explained on the basis of loss of
size selectivity since in this size range the clearance of neutral
dextrans was decreased in experimental rabbits. These results
indicate loss of charge selectivity as well. Thus in rabbit
membranous nephropathy there is loss of both size and charge
selectivity.
Myers and colleagues have recently studied the fractional
clearance of neutral dextrans in human subjects with membra-
nous nephropathy [26]. They showed that for dextrans below a
molecular radius of 50 A the clearance compared to healthy
controls was decreased, but for molecules greater than this
radius the clearance was increased which is similar to what we
found in experimental membranous nephropathy. But they did
not study the clearance of charged dextrans and so were unable
to identify whether there was a charge-selective defect as well.
Correlated with this loss of charge-selectivity, we found
changes in glomerular heparan sulfate. Total [35S] sulfate incor-
poration into glycosaminoglycans was not different between
control and experimental rabbits, but in experimental rabbits
15 25 35 45 55 65
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more [355] sulfate was incorporated into chondroitin sulfate and
less into heparan sulfate (40% vs. 21%). On ion exchange
chromatography of labeled heparan sulfate, more of this gly-
cosaminoglycan from experimental glomeruli eluted in the
lower molarity salt (1.0 M NaCl). This was supported by the
presence of more total heparan sulfate, as quantitated by uronic
acid, from experimental animals at the lower molarity. But the
specific activity of the heparan sulfate from experimental ani-
mals in the lower molarity buffer fraction was increased com-
pared to controls. Thus, a significant portion of the heparan
sulfate from experimental animals appeared structurally altered
and functioned as if it had a lower overall negative charge. The
shift in elution cannot be due to a change in molecular weight of
the heparan sulfate from experimental rabbits since no differ-
ences were found.
This change in the structure of gloinerular heparan sulfate
from experimental animals was substantiated by the results of
the enzymatic degradation. Much less of the heparan sulfate
from experimental animals in the 1.0 M NaC1 fraction was
degraded to disaccharides by heparinase as compared to con-
trols (9% vs. 21%). This suggests the change in the structure of
the heparan sulfate may be due to loss of heparin-like segments
[25].
These data indicate that in this model of experimental mem-
branous nephropathy heparan sulfate synthesis appears to be
somewhat altered, leading to a change in structure which leads
to a less "effective" negative charge. This change in the
glomerular heparan sulfate as well as the increased percentage
of chondroitin sulfate may contribute to the loss of charge
selectivity found.
Though this change in one of the major glomerular polyanions
is undoubtedly very significant, it does not seem adequate to
explain the massive proteinuria on the basis of loss of charge
selectivity alone. However, even a fairly subtle variation in
heparan sulfate structure and percentage versus chondroitin
sulfate could affect overall basement membrane organization.
The heparan sulfate proteoglycan molecules form a meshwork
of gel matrix [27]. The hydrophilic properties of the proteogly-
cans keep this matrix hydrated. The polysaccharide chains are
thought to act as "spacers" and may play a role in determining
the porosity of the basement membrane and also glomerular
capillary hydraulic permeability which is the major determinant
of the glomerular permeability coefficient and the glomerular
filtration rate. Any change in proteoglycan structure could alter
the gel matrix of the glomerular basement membrane in a
manner similar to that observed in in vitro gel systems [28, 29].
The filtration characteristics of the glomerular capillary which
are due to steric hindrance would be altered and thus would
lead to a loss of size selectivity as well. Changes in glomerular
filtration rate might also occur.
Recently Blantz and colleagues have reported in rat membra-
nous nephropathy, Heymann nephritis, that the onset of pro-
teinuria correlated with a reduction in glomerular permeability
coefficient and in glomerular filtration rate [30]. We found
similar reductions in glomerular filtration rate in the rabbit
model. This reduction in glomerular permeability coefficient
and filtration rate could be related to an alteration in the
glomerular basement membrane caused by the change in hepa-
ran sulfate structure.
The importance of heparan sulfate in the maintenance of
glomerular permeability is supported by data showing that
when heparan sulfate is removed by enzyme digestion, perme-
ability to both ferritin and albumin is increased [31, 32], and, in
addition, in a variety of models of increased glomerular perme-
ability, a decreased number of glomerular anionic sites have
been found by staining reactions, which was thought to explain
at least some of the increased permeability [33, 34]. We
demonstrate here that no changes in total glycosaminoglycan
content occurs, but heparan sulfate structure may be altered
which can have a profound effect on glomerular permeability.
In membranous nephropathy the immune deposits are almost
exclusively located in the subepithelial space. Work in both
rabbit and rat models of membranous nephropathy has shown
that the terminal complement pathway is required for injury to
occur [15, 35]. These complement components are acting on the
glomerular epithelial cell membrane [35]. This cell is also
known to be the main site of synthesis of glomerular heparan
sulfate [36—38]. Thus, injury to the epithelial cell could lead to
synthesis of an altered heparan sulfate molecule perhaps due to
a repair process, leading to altered permeability and filtration of
the glomerular capillary wall. The visceral epithelial cell may
also be important for synthesis of other basement membrane
components and interference with their synthesis, transport or
assembly into the glomerular basement membrane could lead to
altered glomerular permeability as well.
There have been few studies which have characterized hepa-
ran sulfate in models of altered glomerular permeability. This is
the first study of heparan sulfate in a model of membranous
nephropathy. We have recently reported that in puromycin
aminonucleoside nephrosis in the rat, a model of toxic nephrop-
athy, heparan sulfate levels are normal, the structure altered
and its synthesis diminished in the early stages of this disease
(39). Thus in two models heparan sulfate levels appear normal
but its structure is altered. Kanwar and colleagues have also
recently shown that in established puromycin nephrosis the
core protein of heparan sulfate proteoglycan is unchanged but
there is a mild increase in charge density of the de novo
synthesized heparan sulfate similar to what we found in estab-
lished puromycin nephrosis (40). Changes in heparan sulfate
structure may be important in many disorders of altered gb-
merular permeability.
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